BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 34339757)

  • 1. Engineering the aortic valve extracellular matrix through stages of development, aging, and disease.
    Scott AJ; Simon LR; Hutson HN; Porras AM; Masters KS
    J Mol Cell Cardiol; 2021 Dec; 161():1-8. PubMed ID: 34339757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Native aortic valve derived extracellular matrix hydrogel for three dimensional culture analyses with improved biomimetic properties.
    Nehrenheim L; Raschke S; Stefanski A; Barth M; Isabel Selig J; Barbian A; Fernández-Colino A; Stühler K; Mela P; Albert A; Lichtenberg A; Akhyari P
    Biomed Mater; 2019 Apr; 14(3):035014. PubMed ID: 30769335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneous multi-laminar tissue constructs as a platform to evaluate aortic valve matrix-dependent pathogenicity.
    Monroe MN; Nikonowicz RC; Grande-Allen KJ
    Acta Biomater; 2019 Oct; 97():420-427. PubMed ID: 31362141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extracellular Matrix in Calcific Aortic Valve Disease: Architecture, Dynamic and Perspectives.
    Di Vito A; Donato A; Presta I; Mancuso T; Brunetti FS; Mastroroberto P; Amorosi A; Malara N; Donato G
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of polycaprolactone fibrous scaffold for heart valve tissue engineering.
    Jana S; Bhagia A; Lerman A
    Biomed Mater; 2019 Oct; 14(6):065014. PubMed ID: 31593551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simulation of early calcific aortic valve disease in a 3D platform: A role for myofibroblast differentiation.
    Hjortnaes J; Goettsch C; Hutcheson JD; Camci-Unal G; Lax L; Scherer K; Body S; Schoen FJ; Kluin J; Khademhosseini A; Aikawa E
    J Mol Cell Cardiol; 2016 May; 94():13-20. PubMed ID: 26996755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcification and extracellular matrix dysregulation in human postmortem and surgical aortic valves.
    Gomez-Stallons MV; Tretter JT; Hassel K; Gonzalez-Ramos O; Amofa D; Ollberding NJ; Mazur W; Choo JK; Smith JM; Kereiakes DJ; Yutzey KE
    Heart; 2019 Nov; 105(21):1616-1621. PubMed ID: 31171628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transforming growth factor-β1 promotes fibrosis but attenuates calcification of valvular tissue applied as a three-dimensional calcific aortic valve disease model.
    Jenke A; Kistner J; Saradar S; Chekhoeva A; Yazdanyar M; Bergmann AK; Rötepohl MV; Lichtenberg A; Akhyari P
    Am J Physiol Heart Circ Physiol; 2020 Nov; 319(5):H1123-H1141. PubMed ID: 32986963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The progression of calcific aortic valve disease through injury, cell dysfunction, and disruptive biologic and physical force feedback loops.
    Li C; Xu S; Gotlieb AI
    Cardiovasc Pathol; 2013; 22(1):1-8. PubMed ID: 22795219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Label-free optical biomarkers detect early calcific aortic valve disease in a wild-type mouse model.
    Tandon I; Johns S; Woessner A; Perez J; Cross D; Ozkizilcik A; Muldoon TJ; Vallurupalli S; Padala M; Quinn KP; Balachandran K
    BMC Cardiovasc Disord; 2020 Dec; 20(1):521. PubMed ID: 33308143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a bi-layered cryogenic electrospun polylactic acid scaffold to study calcific aortic valve disease in a 3D co-culture model.
    Stadelmann K; Weghofer A; Urbanczyk M; Maulana TI; Loskill P; Jones PD; Schenke-Layland K
    Acta Biomater; 2022 Mar; 140():364-378. PubMed ID: 34839029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multimodality and molecular imaging of matrix metalloproteinase activation in calcific aortic valve disease.
    Jung JJ; Razavian M; Challa AA; Nie L; Golestani R; Zhang J; Ye Y; Russell KS; Robinson SP; Heistad DD; Sadeghi MM
    J Nucl Med; 2015 Jun; 56(6):933-8. PubMed ID: 25908827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelial to mesenchymal transformation is induced by altered extracellular matrix in aortic valve endothelial cells.
    Dahal S; Huang P; Murray BT; Mahler GJ
    J Biomed Mater Res A; 2017 Oct; 105(10):2729-2741. PubMed ID: 28589644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone Morphogenetic Protein Signaling Is Required for Aortic Valve Calcification.
    Gomez-Stallons MV; Wirrig-Schwendeman EE; Hassel KR; Conway SJ; Yutzey KE
    Arterioscler Thromb Vasc Biol; 2016 Jul; 36(7):1398-405. PubMed ID: 27199449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Noggin attenuates the osteogenic activation of human valve interstitial cells in aortic valve sclerosis.
    Poggio P; Sainger R; Branchetti E; Grau JB; Lai EK; Gorman RC; Sacks MS; Parolari A; Bavaria JE; Ferrari G
    Cardiovasc Res; 2013 Jun; 98(3):402-10. PubMed ID: 23483047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of calcific aortic valve disease: Do we know enough for new clinical trials?
    Kostyunin AE; Yuzhalin AE; Ovcharenko EA; Kutikhin AG
    J Mol Cell Cardiol; 2019 Jul; 132():189-209. PubMed ID: 31136747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Could activated tissue remodeling be considered as early marker for progressive valve degeneration? Comparative analysis of checkpoint and ECM remodeling gene expression in native degenerating aortic valves and after bioprosthetic replacement.
    Yeghiazaryan K; Skowasch D; Bauriedel G; Schild H; Golubnitschaja O
    Amino Acids; 2007 Jan; 32(1):109-14. PubMed ID: 16874466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanisms involved in high glucose-induced valve calcification in a 3D valve model with human valvular cells.
    Vadana M; Cecoltan S; Ciortan L; Macarie RD; Tucureanu MM; Mihaila AC; Droc I; Butoi E; Manduteanu I
    J Cell Mol Med; 2020 Jun; 24(11):6350-6361. PubMed ID: 32307869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aortic valve disease and treatment: the need for naturally engineered solutions.
    Butcher JT; Mahler GJ; Hockaday LA
    Adv Drug Deliv Rev; 2011 Apr; 63(4-5):242-68. PubMed ID: 21281685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tri-layered elastomeric scaffolds for engineering heart valve leaflets.
    Masoumi N; Annabi N; Assmann A; Larson BL; Hjortnaes J; Alemdar N; Kharaziha M; Manning KB; Mayer JE; Khademhosseini A
    Biomaterials; 2014 Sep; 35(27):7774-85. PubMed ID: 24947233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.